The 55-year-old Las Vegas resident faces nine federal counts in the Northern District of Texas, where prosecutors allege that skin-substitute arrangements disguised as discounts drove hundreds of millions of dollars in payments from taxpayer-funded health programs.
WASHINGTON, D.C. — Federal prosecutors have indicted Michael McMillan, a 55-year-old Las Vegas resident and owner of Protectus LLC, over an alleged nationwide wound-care scheme that authorities say transformed expensive skin-substitute reimbursements into unlawful profits for distributors, sales representatives, and participating medical providers.
The criminal case, filed in the Northern District of Texas under case number 3:26-cr-00310, accuses McMillan of health care fraud, offering and paying illegal health care kickbacks, and conducting seven monetary transactions involving property that prosecutors contend was derived from criminal activity.
According to the federal indictment filed against Michael McMillan, the alleged conduct operated from approximately May 2019 through at least February 2026 and caused Medicare, TRICARE, and CHAMPVA to pay roughly $268 million for skin-substitute claims generated through the challenged business model.
The indictment contains allegations rather than proven facts; McMillan remains presumed innocent unless prosecutors establish every charged element beyond a reasonable doubt, and neither the enormous payment figure nor the government’s early asset seizures independently determine whether any criminal violation occurred.
A Distributor-Focused Wound-Care Prosecution
Unlike wound-care prosecutions centered primarily on clinicians who allegedly applied unnecessary products or fabricated patient records, the McMillan case approaches the market from the distribution side, portraying Protectus and related entities as the financial engine connecting product selection, provider reimbursement, sales commissions, and alleged kickback payments.
Prosecutors say McMillan offered various skin-substitute products to physicians, podiatrists, nurse practitioners, and other medical providers through an arrangement that reduced their financial risk while guaranteeing substantial returns whenever a federal health program approved and paid an associated wound-care claim.
Under the alleged structure, providers received products without making an upfront payment, owed Protectus nothing when a reimbursement claim was denied, and became responsible for paying the distributor only after Medicare or another participating government program transmitted reimbursement for the billed skin substitute.
Once payment arrived, the indictment says Protectus generally invoiced the provider for approximately 60 to 70 percent of the program reimbursement, allowing the provider to retain the remaining 30 to 40 percent and potentially earn thousands of dollars from each successful claim.
Prosecutors characterize that retained margin as remuneration intended to induce providers to order Protectus products and bill federal programs, while the defense will be entitled to contest whether the transactions were unlawful inducements, legitimate commercial discounts, protected arrangements, or something materially different from the government’s description.
Rebates, Discounts, and the Anti-Kickback Question
The central legal dispute is not whether businesses may ever provide volume pricing, rebates, credit terms, or ordinary discounts, because federal health care commerce permits many legitimate arrangements, but whether the economic terms were knowingly designed to reward purchasing decisions reimbursed by federal programs.
The indictment alleges that labels such as rebates and discounts concealed the arrangement’s real purpose, making the payment structure function as a profit split that rewarded providers for choosing, ordering, and submitting claims for skin substitutes supplied through McMillan’s Protectus network.
Prosecutors further allege that McMillan and Protectus paid approximately $94 million to participating medical providers, an amount the government describes as illegal kickbacks connected to the approximately $268 million that Medicare, TRICARE, and CHAMPVA allegedly paid on the resulting claims.
The government also claims Protectus paid approximately $27 million to sales representatives whose compensation was tied to reimbursements produced by providers they recruited, creating another financial layer that investigators will likely examine through contracts, commission records, bank transfers, communications, claim histories, and testimony from industry participants.
Those figures must be understood as overlapping components rather than automatically added into a larger loss total, because the indictment separately alleges that McMillan and Protectus received approximately $174 million from the program payments before money flowed through provider margins, sales commissions, operating accounts, and other challenged transactions.
Why Skin Substitutes Generated Extraordinary Scrutiny
Skin substitutes are advanced wound-care products clinicians use to support healing in difficult chronic wounds, including certain diabetic foot ulcers and venous leg ulcers, and they can provide legitimate medical benefits when properly selected, documented, sized, applied, and monitored for an eligible patient.
The products became a prominent enforcement target because reimbursement could be calculated using product-specific rates and the amount applied, producing unusually large payments when expensive graft material covered substantial wound areas or when providers repeatedly used high-cost products across multiple treatment sessions.
That payment environment created room for legitimate innovation and patient care, but it also produced powerful financial incentives that federal analysts could examine by comparing provider volumes, per-patient spending, product preferences, application frequency, geographic patterns, acquisition costs, and reimbursement behavior against broader clinical and billing norms.
The McMillan indictment does not make every skin-substitute application fraudulent merely because a product was expensive, and medical necessity remains distinct from the alleged kickback theory, although prosecutors contend that claims generated through illegal remuneration or material pricing misrepresentations were ineligible for government payment.
That distinction matters because a reimbursement dispute, coding error, contract disagreement, or failure to follow administrative guidance does not automatically become a criminal fraud case, which generally requires the government to prove the defendant possessed the legally required knowledge and acted with the charged fraudulent or unlawful purpose.
How Acquisition Cost Became Part of the Fraud Theory
Prosecutors allege that participating providers submitted claims containing inaccurate information about their true acquisition costs, an issue that becomes especially important when rebates, discounts, contingent invoices, or post-payment adjustments materially reduce what a provider ultimately pays for the product used during treatment.
From the government’s perspective, a provider cannot present one economic picture to a reimbursement program while privately operating under another arrangement that guarantees a large retained margin, particularly when the undisclosed terms allegedly influenced both the product decision and the amount paid from public funds.
The defense can challenge whether billing instructions were sufficiently clear, whether claimed acquisition-cost entries were actually false under the applicable rules, whether McMillan controlled the providers’ submissions, and whether he knowingly participated in any material misrepresentation rather than relying upon independent clinicians, billers, or compliance professionals.
Those questions will require claim-level evidence rather than broad arithmetic alone, because prosecutors ultimately must connect the charged defendant’s conduct and mental state to the alleged scheme, while the defense may argue that legitimate product delivery, clinical value, or ambiguous reimbursement guidance undermines the government’s sweeping interpretation.
Nine Counts and Serious Financial Exposure
Count One charges health care fraud under Title 18, Section 1347, which requires proof that McMillan knowingly and willfully executed or attempted to execute a scheme to defraud a health care benefit program or obtain program money through materially false or fraudulent representations.
Count Two charges the offer and payment of illegal remuneration under the federal Anti-Kickback Statute, and prosecutors must establish that McMillan knowingly and willfully offered or paid something of value to induce or reward purchasing, ordering, recommending, or arranging federally reimbursable items or services.
Counts Three through Nine charge monetary transactions in criminally derived property under Title 18, Section 1957, a statute generally directed at transactions exceeding $10,000 that involve proceeds derived from specified unlawful activity and move through or involve qualifying financial institutions.
Those seven financial counts allow prosecutors to focus jurors on particular transfers instead of relying exclusively upon the complete business history, while also permitting the government to trace alleged proceeds from federal reimbursements into accounts, investments, property purchases, or other transactions identified during the investigation.
A standard health care fraud conviction can carry up to ten years of imprisonment, an Anti-Kickback Statute conviction can also carry up to ten years, and each Section 1957 conviction can carry up to ten years, although statutory maximums do not predict an actual sentence.
Any eventual punishment would depend upon convictions, judicial findings, applicable sentencing guidelines, proven loss, role adjustments, criminal history, acceptance of responsibility, restitution issues, and other statutory considerations, rather than simply multiplying the number of counts by each offense’s theoretical maximum penalty.
Approximately $35 Million in Assets Seized
Federal authorities say they seized assets valued at approximately $35 million in connection with the McMillan investigation, while related court notices identify interests in real property and the indictment seeks forfeiture of assets allegedly traceable to health care fraud, kickbacks, or unlawful monetary transactions.
Asset seizure can preserve property while a case proceeds, preventing dissipation before a possible forfeiture decision, but government possession at this preliminary stage does not establish that the property was criminally derived or that prosecutors will ultimately retain every seized asset.
McMillan may challenge tracing, ownership, valuation, probable cause, substitute-asset theories, and the relationship between particular property and charged conduct, while third parties claiming legitimate interests may also pursue procedures designed to protect assets that do not legally belong to the defendant.
The financial litigation may therefore unfold alongside the criminal prosecution, making bank records, real-estate documents, corporate ledgers, invoices, tax materials, and transaction histories important not only for proving alleged fraud but also for determining what property can lawfully be forfeited after adjudication.
Part of the 2026 National Health Care Fraud Takedown
The McMillan indictment emerged during the Justice Department’s 2026 National Health Care Fraud Takedown, a coordinated enforcement initiative that announced charges against 455 defendants, including 90 doctors and other licensed medical professionals, over alleged schemes involving more than $6.5 billion in false claims.
The national action reached 56 federal districts and 45 states and territories, and officials reported more than $182 million in seized cash, vehicles, jewelry, and other property, along with extensive administrative measures against providers whose billing privileges or program participation drew urgent scrutiny.
In North Texas alone, authorities announced seven cases involving 13 defendants and more than $365 million in alleged fraudulent billing, with the McMillan matter representing the largest disclosed dollar figure among that district’s cases and the only local prosecution focused principally on skin-substitute distribution.
An independent NBC 5 Dallas-Fort Worth report on the North Texas crackdown described allegations spanning wound-care products, laboratory testing, transcranial magnetic stimulation, electroencephalography, hospice services, COVID-19 test kits, and durable medical equipment billed to federal programs or other insurers.
The McMillan investigation was attributed to the Federal Bureau of Investigation’s Dallas Field Office, the Department of Health and Human Services Office of Inspector General, the Defense Criminal Investigative Service, and the Department of Veterans Affairs Office of Inspector General.
Each agency brings a different institutional interest, including protecting Medicare funds, preserving military health benefits, safeguarding veterans’ programs, tracing interstate financial activity, and identifying provider or supplier conduct that may endanger patients while diverting resources from legitimate care.
Data Analytics Changed the Enforcement Landscape
Modern health care fraud investigations increasingly begin with large-scale billing analysis that can identify sudden growth, extreme outliers, repeated use of unusually expensive products, suspicious provider networks, improbable treatment patterns, and financial relationships that would have been far harder to detect through traditional complaint-driven investigations alone.
In a skin-substitute case, investigators can compare product codes, wound sizes, application dates, reimbursement values, beneficiary histories, ordering clinicians, supplier relationships, and regional patterns before subpoenas, interviews, search warrants, or cooperating witnesses provide the human evidence necessary to explain what the numbers actually mean.
Analytics can generate powerful investigative leads, but statistical abnormality is not itself proof of criminal intent, because specialty practices, complex patients, regional referral patterns, novel products, or lawful business growth may produce unusual data without establishing that anyone knowingly joined a fraudulent arrangement.
The evidentiary contest will therefore concern whether the government’s data corresponds with communications, contracts, invoices, payment records, training materials, and witness testimony demonstrating unlawful purpose, or whether the defense can offer credible commercial and clinical explanations for activity portrayed as suspicious.
Compliance Lessons for Providers and Distributors
Medical providers considering skin substitutes should document patient eligibility, conservative treatment history, wound measurements, product selection, discarded material, application details, follow-up results, acquisition price, rebates, and every financial relationship that could influence a federally reimbursed ordering decision.
Distributors should structure discounts prospectively, document commercially reasonable terms, separate compliant sales compensation from the value or volume of federal program business, and obtain specialized legal review whenever providers receive unusually large, reimbursement-contingent margins with little or no downside risk.
Billing teams must also understand the complete economic transaction rather than relying only upon a sticker price, because credits, rebates, post-payment adjustments, free goods, replacement guarantees, or contingent obligations may affect the accuracy of pricing information presented to a government program.
For executives, clinicians, and organizations confronting public allegations, Amicus International Consulting provides broader material concerning lawful cross-border planning, identity integrity, due diligence, and reputational exposure, while consistently distinguishing legitimate privacy protection from concealment intended to obstruct regulators, courts, or law-enforcement authorities.
Its reputation rebuilding and crisis-management resources likewise emphasize accurate public information, documented corrections, lawful communications, and sustained credibility, principles that become particularly important when an indictment creates lasting search results before evidence has been tested through adversarial proceedings.
What Prosecutors Must Prove
The government’s headline figures may shape public attention, but a jury would still have to assess whether prosecutors proved the charged scheme, McMillan’s knowing and willful participation, the alleged inducement behind the payments, the falsity and materiality of relevant representations, and the criminal origin of funds involved in each financial count.
The defense can test cooperating witnesses for bias, demand full communications rather than selected excerpts, examine whether providers made independent decisions, dispute loss and kickback calculations, challenge ambiguous billing guidance, and argue that lawful discounts or legitimate compensation explain transactions prosecutors highlighted.
The Anti-Kickback Statute includes exceptions and regulatory safe harbors, although falling outside a safe harbor does not automatically establish criminal liability, and the parties may sharply disagree about commercial reasonableness, discount disclosure, intent, control, reliance, and the practical operation of Protectus agreements.
Likewise, program payments alone do not prove every underlying service lacked value, and providing actual products does not necessarily defeat a fraud theory if prosecutors show that undisclosed kickbacks or material misrepresentations corrupted the claims and payment decisions.
What Happens Next in the Michael McMillan Case
The prosecution will proceed through arraignment, discovery, pretrial motions, expert analysis, evidentiary disputes, and possible negotiations, with Assistant United States Attorneys Marty Basu and Chad Meacham identified by federal officials as the prosecutors handling the Northern District of Texas case.
Potential motions could address seizure procedures, warrant evidence, expert testimony, billing guidance, statutory interpretation, venue, claim sampling, loss methodology, and admissibility of communications, while discovery may reveal additional context that materially strengthens, narrows, or contradicts the allegations summarized publicly.
McMillan may ultimately contest the case at trial, negotiate a resolution, or seek dismissal of particular counts, but no fair account can predict an outcome before the defense receives the evidence and the court resolves the factual and legal disputes presented.
For now, the indictment places the Protectus business model at the center of the federal government’s widening skin-substitute enforcement campaign, illustrating how reimbursement design, provider profit, distributor compensation, and billing disclosures can converge into a major criminal investigation with national consequences.
The case also delivers a broader warning across the wound-care market: a commercial term described as a discount will be judged by its actual purpose, disclosure, and economic effect, especially when taxpayer-funded programs absorb the cost, and providers receive unusually dependable profits.
Most importantly, every allegation against Michael McMillan remains unproven; the burden belongs entirely to the United States, and the constitutional presumption of innocence continues unless and until a unanimous jury or a valid guilty plea establishes criminal responsibility beyond the required legal standard.